Algiax Pharmaceuticals Announces Positive Interim Analysis of Phase 2a Study with Lead Candidate AP-325 in Chronic Neuropathic Pain

-- Data Monitoring Committee recommends continuation of the study with no safety alerts within the study population -- -- Company is ramping up patient recruitment by doubling number of countries

Related Keywords

Germany ,Spain ,Italy ,Czech Republic ,Belgium ,France ,Alexander Siebert ,Ingo Lehrke ,Claudia Sommer ,International Association For The Study Of Pain ,Data Monitoring Committee ,Trophic Communications ,Algiax Pharmaceuticals Gmb ,Algiax Pharmaceuticals ,Monitoring Committee ,Chief Executive Officer ,International Association ,Pain Intensity Numerical Rating Scale ,Pharmaceuticals Gmbh ,Gefallene Big Techs ,Algiax ,Pharmaceuticals ,Nnounces ,Positive ,Interim ,Analysis ,Hase ,Study ,Head ,Candidate ,Hronic ,Neuropathic ,Rain ,